Why its interesting: The actives are familiar, but SkinCeuticals stands out by testing specifically on GLP-1 patients making the positioning fresher than the formula itself
And so far Im happy with the product and this company
These are pathway-level associations: the test does not predict response to a specific medication and does not determine which one to take the provider decides
What makes them particularly exciting is that their benefits go beyond weight loss, with clinical trials showing improvements in blood sugar control, inflammation, and even reductions in cardiovascular events for certain patients. Although most clinical trials to date have focused on adult populations broadly (not women in menopause specifically) emerging research suggests GLP-1 therapies may be particularly helpful during estrogen-deficient states such as menopause, when the risk of metabolic syndrome rises and fat distribution often shifts toward increased abdominal adiposity
Insulin and sulfonylureas carry a higher hypoglycemia risk when combined with retatrutide
These conditions can include neurodegenerative diseases, i.e., Parkinsons disease or rheumatoid arthritis, cystic fibrosis, and other autoimmune diseases